Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019

Ji Yun Noh, Jeong Eun Kwak, Jeong Sun Yang, Soon Young Hwang, Jin Gu Yoon, Hye Seong, Hakjun Hyun, Chae Seung Lim, Soo Young Yoon, Jungsang Ryou, Joo Yeon Lee, Sung Soon Kim, Su Hyung Park, Hee Jin Cheong, Woo Joo Kim, Eui Cheol Shin, Joon Young Song

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

BACKGROUND: There is insufficient data on the longevity of immunity acquired after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We aimed to evaluate the duration of SARS-CoV-2-specific humoral and cellular immunity according to the clinical severity of coronavirus disease 2019 (COVID-19). The study population comprised asymptomatic (n = 14), symptomatic/nonpneumonic (n = 42), and pneumonic (n = 41) patients. RESULTS: The anti-SARS-CoV-2 immunoglobulin class G and neutralizing antibody (NAb) titers lasted until 6 months after diagnosis, with positivity rates of 66.7% and 86.9%, respectively. Older age, prolonged viral shedding, and accompanying pneumonia were more frequently found in patients with sustained humoral immunity. Severe acute respiratory syndrome coronavirus 2-specific T-cell response was strongly observed in pneumonic patients and prominent in individuals with sustained humoral immunity. CONCLUSIONS: In conclusion, most (>85%) patients carry NAb until 6 months after diagnosis of SARS-CoV-2 infection, providing insights for establishing vaccination strategies against COVID-19.

Original languageEnglish
Pages (from-to)754-763
Number of pages10
JournalThe Journal of infectious diseases
Volume224
Issue number5
DOIs
Publication statusPublished - 2021 Sep 1

Keywords

  • cellular immunity
  • COVID-19
  • humoral immunity
  • longevity
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Longitudinal Assessment of Antisevere Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019'. Together they form a unique fingerprint.

Cite this